Colon News and Research

RSS

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Nearly half of all states are falling short on legislative solutions to prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN). However, despite budget crises in several states, some state lawmakers still made positive progress in the fight against a disease that will kill an estimated 569,000 people in the United States this year.

29 Jul 2010

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

USPTO grants two patents for Leto Medical's COS technology

Leto Medical, LLC, a privately held, early-stage medical device company, announced today that the United States Patent and Trademark Office has granted the company two patents (7,765,006 and 7,765,007) for its breakthrough Continent Ostomy System technology, a system of products that will restore continence control to individuals with colostomies.

28 Jul 2010

Clinicians in rural hospitals demonstrate high standard of care to patients: Study

Smaller, rural hospitals may be quicker and more efficient at implementing surgical safety initiatives than their larger, urban counterparts, and are capable of providing a standard of surgical care that is at par with major hospitals that provide a comprehensive array of care services, according to an 18-month series of studies led by researchers from the University of Louisville Department of Surgery.

28 Jul 2010

CTC is not cost effective compared with colonoscopy: Study

A UNC physician authored an editorial in the July 27 online issue of the Journal of the National Cancer Institute (JNCI) commenting on results of an analysis of the cost effectiveness of colonoscopy versus computed tomographic colonography (CTC).The cost effectiveness analysis concluded that CTC or virtual colonoscopy is not cost effective compared with colonoscopy if reimbursed at the same rate as colonoscopy

28 Jul 2010

MabCure's MAbs 94% accurate in identifying ovarian cancer

Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.

28 Jul 2010

New York Times article highlights potential value of early cancer detection technology

Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.

27 Jul 2010

NCCN enters into collaboration to introduce Proventys CDS Oncology system

The National Comprehensive Cancer Network and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology system, a first-of-its-kind Web platform that arms oncologists with expert recommendations and evidence facilitating the delivery of high-quality, individualized patient care.

27 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

LCA survey sheds more light on why support for lung cancer people remains low

A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."

23 Jul 2010

Preclinical data of new acamprosate prodrug to be presented at International Fragile X Conference

XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.

23 Jul 2010

New model of inflammatory bowel disease explores interactions of cells in immune system

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have constructed a mathematical and computational model of inflammatory bowel disease that allows researchers to simulate the cellular and molecular changes underlying chronic inflammation in humans. The model allows scientists to explore different interactions of cells in the immune system, check how these cells are linked to inflammation in the colon, and identify intervention points to perhaps stop the disease in its tracks.

23 Jul 2010

BioTime announces 21 new stem cell products for sale

BioTime, Inc. announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line.

22 Jul 2010

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

A recent questionnaire submitted to a group of patients at one of the nation's largest general hospitals suggests that a significant number of patients, who have previously refused colorectal cancer screening, are willing to undergo computed tomography colonography (CTC) (or virtual colonoscopy), but not willing to pay for the exam themselves when not covered by insurance, according to a study in the August issue of the American Journal of Roentgenology (www.ajronline.org).

22 Jul 2010

Researchers block stress responses in cancer surgery patients

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

22 Jul 2010

GE, MSKCC launch colon cancer study

A team of scientists at GE Global Research, the technology development arm for the GE, has launched a study with Memorial Sloan-Kettering Cancer Center, (MSKCC) one of the world's premier cancer centers, to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.

22 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Combined technologies offer promise for detecting colon cancer in women

A team led by a Northwestern University biomedical engineer has found that combining novel optical technologies with a common colon cancer screening test may allow doctors to more accurately detect the presence of colon cancer, particularly in women.

20 Jul 2010

Colon News and Research

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

USPTO grants two patents for Leto Medical's COS technology

Clinicians in rural hospitals demonstrate high standard of care to patients: Study

CTC is not cost effective compared with colonoscopy: Study

MabCure's MAbs 94% accurate in identifying ovarian cancer

New York Times article highlights potential value of early cancer detection technology

NCCN enters into collaboration to introduce Proventys CDS Oncology system

Axela acquires Xceed Molecular

LCA survey sheds more light on why support for lung cancer people remains low

Preclinical data of new acamprosate prodrug to be presented at International Fragile X Conference

New model of inflammatory bowel disease explores interactions of cells in immune system

BioTime announces 21 new stem cell products for sale

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

Researchers block stress responses in cancer surgery patients

GE, MSKCC launch colon cancer study

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Researchers find that increase in leptin may promote colorectal neoplasms

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Combined technologies offer promise for detecting colon cancer in women

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News